Bayer receives MHRA approval for Kerendia® (finerenone) in adults with heart failure with LVEF ≥ 40 %
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Kerendia® (finerenone), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of symptomatic chronic heart failure (HF)…